Quanterix (QTRX) Expected to Announce Earnings on Wednesday
by Renee Jackson · The Cerbat GemQuanterix (NASDAQ:QTRX – Get Free Report) is projected to issue its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Quanterix to post earnings of ($0.4850) per share and revenue of $37.2060 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.
Quanterix (NASDAQ:QTRX – Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.11). The company had revenue of $41.40 million for the quarter, compared to analysts’ expectations of $37.95 million. Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Quanterix Price Performance
NASDAQ:QTRX traded up $0.03 on Monday, reaching $3.43. 87,360 shares of the company’s stock were exchanged, compared to its average volume of 784,852. The stock has a fifty day simple moving average of $4.26 and a 200-day simple moving average of $5.66. The firm has a market cap of $161.42 million, a price-to-earnings ratio of -1.37 and a beta of 1.15. Quanterix has a 52 week low of $2.95 and a 52 week high of $8.77.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. boosted its stake in Quanterix by 14.0% during the second quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock worth $28,175,000 after buying an additional 521,639 shares during the period. Vanguard Group Inc. boosted its stake in Quanterix by 4.7% during the third quarter. Vanguard Group Inc. now owns 2,647,515 shares of the company’s stock worth $14,376,000 after buying an additional 118,565 shares during the period. Millennium Management LLC boosted its stake in Quanterix by 9,880.2% during the third quarter. Millennium Management LLC now owns 1,209,199 shares of the company’s stock worth $6,566,000 after buying an additional 1,197,083 shares during the period. Geode Capital Management LLC boosted its stake in Quanterix by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 1,073,967 shares of the company’s stock worth $6,832,000 after buying an additional 62,077 shares during the period. Finally, State Street Corp boosted its stake in Quanterix by 9.0% during the fourth quarter. State Street Corp now owns 893,401 shares of the company’s stock worth $5,682,000 after buying an additional 73,867 shares during the period. 86.48% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on QTRX shares. Wall Street Zen lowered shares of Quanterix from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Canaccord Genuity Group reduced their target price on shares of Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a research report on Monday, April 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Quanterix in a research report on Tuesday, April 21st. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Quanterix currently has an average rating of “Reduce” and an average target price of $4.00.
View Our Latest Stock Report on Quanterix
About Quanterix
Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.
The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.